Holen Sie sich die Stockscreener-App
2.90
0.35%
0.010
Schlusskurs vom Vortag:
$2.89
Offen:
$2.88
24-Stunden-Volumen:
133.14K
Relative Volume:
0.39
Marktkapitalisierung:
$111.10M
Einnahmen:
$2.76M
Nettoeinkommen (Verlust:
$-49.12M
KGV:
-1.9333
EPS:
-1.5
Netto-Cashflow:
$-46.21M
1W Leistung:
+9.43%
1M Leistung:
+1.40%
6M Leistung:
-50.34%
1J Leistung:
-37.23%
1-Tages-Spanne:
$2.79
$2.94
1-Wochen-Bereich:
$2.5956
$3.01
52-Wochen-Spanne:
$2.37
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Firmenname
Orchestra Biomed Holdings Inc
Sektor
Branche
Telefon
646-343-9298
Adresse
150 UNION SQUARE DRIVE, NEW HOPE
Vergleichen Sie OBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.90 | 101.53M | 2.76M | -49.12M | -46.21M | -1.50 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | BTIG Research | Buy |
| 2025-01-02 | Eingeleitet | Barclays | Overweight |
| 2024-08-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-25 | Eingeleitet | B. Riley Securities | Buy |
| 2024-01-19 | Eingeleitet | Jefferies | Buy |
| 2023-02-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-07 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Orchestra Biomed Holdings Inc Aktie (OBIO) Neueste Nachrichten
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MyChesCo
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation - MSN
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Targ - GuruFocus
Barclays PLC Boosts Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Wells Fargo & Company MN Buys 3,992 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed HoldingsBreakthrough Device Designation Gives Speculative Optimism - Seeking Alpha
Orchestra BioMed (OBIO) Surpasses Revenue Estimates with Strong Q1 Growth | OBIO Stock News - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy and IDE Approval for Virtue SAB Trial - Nasdaq
Orchestra BioMed Reports First Quarter 2025 Financial - GlobeNewswire
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - Stock Titan
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
(OBIO) On The My Stocks Page - news.stocktradersdaily.com
Orchestra BioMed receives FDA approval to initiate Virtue Trial - Med-Tech Insights
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
ORCHESTRA BIOMED Earnings Preview: Recent $OBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual - GlobeNewswire
Orchestra BioMed (OBIO) Expands Patent Portfolio for AVIM Therap - GuruFocus
Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewswire
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
BlackRock, Inc. Reduces Stake in Orchestra BioMed Holdings Inc. - GuruFocus
Orchestra BioMed (NASDAQ:OBIO) Price Target Lowered to $12.00 at Barclays - Defense World
Orchestra BioMed Holdings (OBIO) Target Price Adjustment by Barc - GuruFocus
Barclays Adjusts Price Target for Orchestra BioMed (OBIO) | OBIO Stock News - GuruFocus
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Bought by JPMorgan Chase & Co. - Defense World
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon - marketscreener.com
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - The Manila Times
Orchestra BioMed's Revolutionary Sirolimus Balloon Gets FDA Green Light for Head-to-Head Trial - Stock Titan
FDA approves head-to-head trial of Orchestra BioMed’s balloon By Investing.com - Investing.com Canada
Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% – Time to Sell? - Defense World
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed Secures Triple Conference Lineup: CEO Sets Major Investor Presentations - Stock Titan
Analyzing PetVivo (NASDAQ:PETV) & Orchestra BioMed (NASDAQ:OBIO) - Defense World
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Finanzdaten der Orchestra Biomed Holdings Inc-Aktie (OBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):